Contrasting VectivBio (NASDAQ:VECT) & Tectonic Therapeutic (NASDAQ:TECX)

VectivBio (NASDAQ:VECT) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

62.6% of Tectonic Therapeutic shares are held by institutional investors. 9.7% of VectivBio shares are held by company insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares VectivBio and Tectonic Therapeutic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VectivBio	N/A	N/A	N/A
Tectonic Therapeutic	N/A	-50.52%	-47.13%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VectivBio and Tectonic Therapeutic, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VectivBio	0	0	0	0	N/A
Tectonic Therapeutic	0	0	3	1	3.25

Tectonic Therapeutic has a consensus target price of $62.50, indicating a potential upside of 285.33%. Given Tectonic Therapeutic’s higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than VectivBio.

Earnings and Valuation

This table compares VectivBio and Tectonic Therapeutic’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VectivBio	$27.34 million	N/A	-$93.74 million	N/A	N/A
Tectonic Therapeutic	N/A	N/A	$12.16 million	$0.69	23.51

Tectonic Therapeutic has lower revenue, but higher earnings than VectivBio.

Summary

Tectonic Therapeutic beats VectivBio on 5 of the 9 factors compared between the two stocks.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

About Tectonic Therapeutic

Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.